Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1793 results
June 2017
-
Media ReleaseNovartis combination targeted therapy Tafinlar® + Mekinist® receives FDA approval for BRAF V600E mutant metastatic non-small cell lung cancer (NSCLC)Approval provides first targeted treatment in the US specifically for BRAF V600E mutation-positive metastatic NSCLC More than 60% of treatment-naïve and previously treated patients with…
-
Featured NewsAsthma and exercise: why patients can and should stay active
-
Media ReleaseNovartis Phase III study shows ACZ885 (canakinumab) reduces cardiovascular risk in people who survived a heart attackPhase III CANTOS study met the primary endpoint, a composite of heart attack, stroke and cardiovascular death, showing that ACZ885 (canakinumab) in combination with standard of care therapy reduces…
-
Media ReleaseNovartis achieves important regulatory milestone for AMG 334 (erenumab) in migraine prevention with EMA filing acceptanceAMG 334 (erenumab) is the first anti-CGRP monoclonal antibody developed for migraine prevention to receive EMA regulatory filing acceptance Filing is supported by a comprehensive clinical…
-
Helping Syrian refugees manage chronic diseases
Among the many Syrians uprooted by armed conflict are thousands of people with chronic conditions – such as diabetes and heart disease - whose treatment was disrupted when they fled.
-
Media ReleaseNovartis RTH258 (brolucizumab) demonstrates robust visual gains in nAMD patients with a majority on a 12-week injection intervalRTH258 achieved the primary efficacy endpoint of non-inferiority to aflibercept in mean change in BCVA from baseline to week 48[1],[2] in two head-to-head pivotal Phase III studies[3],[4]…
-
Media ReleaseNovartis real world study shows almost half of chronic urticaria patients are not receiving any treatment despite significant disease burdenUrgent need to improve management of chronic urticaria (CU) - a disease that causes itchy, persistent hives and swelling which last more than 6 weeks or recur over months or years - highlighted by…
-
Media ReleaseSandoz receives approval in Europe for Rixathon® (biosimilar rituximab) to treat blood cancers and immunological diseasesEuropean Commission approves Sandoz Rixathon® to treat blood cancers and immunological diseases. Approval expected to broaden patient access to biologics and enable budget-constrained healthcare…
-
Media ReleaseNovartis International AG: New patient survey highlights need for more action to help severe asthma patients gain control of their diseaseLarge-scale European patient survey found that 94% of severe allergic asthma patients were unable to fully control their disease These new data underscore the disconnect between self-…
-
Media ReleaseFDA accepts Sandoz regulatory submission for a generic version of Advair Diskus®FDA accepts Sandoz ANDA for substitutable generic version of Advair Diskus® Sandoz believes its combination product will offer asthma and COPD patients same safety and efficacy as reference…
-
Media ReleaseNovartis' Cosentyx shows sustained improvements in signs and symptoms for both AS and PsA in up to 80% of patients at 3 yearsCosentyx® is the first and only IL-17A inhibitor to show sustained improvements in signs and symptoms of ankylosing spondylitis (AS) and psoriatic arthritis (PsA)[1],[2] Additional data…
-
Media ReleaseNovartis presents data demonstrating efficacy of AMG 334 (erenumab) in migraine prevention at the American Headache Society Annual MeetingData from the comprehensive clinical program show AMG 334 (erenumab) is safe and effective at preventing migraine in patients with 4 or more migraine days per month AMG 334 (erenumab)…
Pagination
- ‹ Previous page
- 1
- …
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- …
- 150
- › Next page